News & Events
Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology
“Dr. Trainer is a global leader in the endocrine community who has treated patients, published extensively and educated physicians on...
READ MOREKOL Call: Paltusotine for the Treatment of Acromegaly
Event Date: November 20, 2020
READ MORECrinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for Treatment of Acromegaly
Crinetics hosts a virtual Key Opinion Leader (KOL) meeting on oral paltusotine for the treatment of acromegaly on Friday, November...
READ MOREThird Quarter 2020 Financial Results and Corporate Update
Positive topline results for Phase 2 trials of oral paltusotine (acromegaly), CRN04777 received Rare Pediatric Disease Designation (congenital hyperinsulinism)
READ MORE32nd Annual Piper Sandler Healthcare Conference
Event Date: December 1–3, 2020
READ MORECompany Conference Call: Review of Phase 2 Paltusotine Results
Event Date: October 26, 2020
READ MOREACROBAT Edge Study of Paltusotine in Acromegaly Met Endpoint
Crinetics announces Paltusotine (for treatment of acromegaly) was observed to be safe and well-tolerated among the 60 participants in the...
READ MORECrinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism
FDA grants rare pediatric disease designation: CRN04777 - investigational, orally available, SST5 agonist developing as treatment for congenital hyperinsulinism.
READ MORECantor Virtual Global Healthcare Conference: Crinetics Pharmaceuticals, Inc.
Event Date: September 15, 2020
READ MORESeptember 14, 2020 10:30 AM EDT : 22nd Annual H.C. Wainwright Global Investment Conference
Event Date: September 14, 2020
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.